hronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation (1) and is the third leading cause of mortality worldwide (2). In the past decades, chest CT has helped to provide valuable insights into COPD. Indeed, CT enables noninvasive, in vivo, and three-dimensional (3D) quantification of the key components of the disease, such as bronchial remodeling (3) and emphysema (4). Evidence of COPD subtypes (1), relationship with genetic variants (5), longitudinal follow-up (6), and mortality (7) have been investigated at CT. More recently, in an era where the advent of artificial intelligence may allow intricate combinations of both morphologic and functional information, lung MRI has emerged as a radiation-free modality for the longitudinal follow-up of lung diseases and (8) to help better identify participant phenotype or predict disease outcomes (9). Studies related to ventilation (10), perfusion (11), dynamic biomarkers (12), and coupling between the cardiovascular and pulmonary systems (13,14) at MRI have been performed. However, there are few studies that evaluated the regional extent of emphysema by using MRI (15-18). Recent advances with ultrashort echo times (UTEs) have been shown to enable submillimeter resolution with good contrast in three dimensions (19,20).